<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958046</url>
  </required_header>
  <id_info>
    <org_study_id>Neu-01.13</org_study_id>
    <nct_id>NCT02958046</nct_id>
  </id_info>
  <brief_title>The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity</brief_title>
  <official_title>Phase 4 Study, Assessing the Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of lansoprazole combination with&#xD;
      domperidone on intragastric acidity and intraesophageal acidity, GERD symptoms, impedance&#xD;
      kinetics, gastric emptying in patients with gastroesophageal reflux disease (GERD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives of the trial to assess the efficacy of lansoprazole in combination with&#xD;
      domperidone on gastric acidity, intraesophageal acidity, GERD symptoms, impedance kinetics&#xD;
      and gastric emptying in patients with GERD.&#xD;
&#xD;
      24 hour pH measurement and gastric emptying test will be done at screening visit and after 7&#xD;
      days of drug treatment. Twelve patients will take one tablet for 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage time of 24-hour intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUC of 24-hour intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The significant increase in total measurements of median pH</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The significant increase in nocturnal measurements of median pH</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrease in reflux symptom index calculated by weekly regurgitation numbers</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The decrease in reflux symptom index calculated by weekly pyrosis numbers</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage time of 24-hour intragastric pH &gt;2 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage time of 24-hour intragastric pH &gt;6 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC of 24-hour intragastric pH &gt;2 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC of 24-hour intragastric pH &gt;6 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage time of 24-hour total intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC of 24-hour total intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of gastric emptying by octanoic acid breath test compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Lansoprazole/Domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DUOLANS 30/30 mg SR tablet per oral, one tablet daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole/Domperidone</intervention_name>
    <description>DUOLANS 30/30 mg SR tablet per oral, one tablet daily</description>
    <arm_group_label>Lansoprazole/Domperidone</arm_group_label>
    <other_name>Duolans</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of GERD with symptoms (i.e. regurgitation, pyrosis) during last one year&#xD;
             with at least 1 or more episodes a week&#xD;
&#xD;
          -  Age ≥ 18 years and &lt;65 years&#xD;
&#xD;
          -  Helicobacter pylori (an infection) negative&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18 and 33 kg/m²&#xD;
&#xD;
          -  pH&gt;4 gastric exposure &lt;25% on a 24-hour dual pH channel monitoring study performed&#xD;
             prior to screening (normal intragastric pH +2SD)&#xD;
&#xD;
          -  Pathologic intraesophageal acidity exposure (DeMeester score &gt;14.75 and/or &gt;4% of pH&lt;4&#xD;
             (at least 21 hours measured)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have food existence at stomach during upper GIS endoscopy, Barrett's stricture, GIS&#xD;
             bleeding, malignite, and all type of GIS pathology to affects the study&#xD;
&#xD;
          -  Have allergy to the study drug or any of the excipients of the formulation&#xD;
&#xD;
          -  Must use of pain relieving medications (NSAIDs) during study, (paracetamol not excess&#xD;
             of 2 gram/day can be used)&#xD;
&#xD;
          -  Use of any concomitant therapy which are drug affects the motility of GIS and acid&#xD;
             secretion&#xD;
&#xD;
          -  Use of prostaglandin analogs and sucralfate&#xD;
&#xD;
          -  Have taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days before&#xD;
             entering the study&#xD;
&#xD;
          -  History of surgery of cholecystectomy&#xD;
&#xD;
          -  Abusing drugs or alcohol&#xD;
&#xD;
          -  Have a major psychiatric disease&#xD;
&#xD;
          -  Use of antidepressant (patient with minor depression or under controlled with drug can&#xD;
             be included)&#xD;
&#xD;
          -  Have suppressed immune system or taken a immunosupressive treatment, including&#xD;
             cortisone.&#xD;
&#xD;
          -  Have malabsorption, gastric outlet obstruction that affects the absorption of drug&#xD;
&#xD;
          -  Must use of drug ketoconazole, iron salts, digoxin, ampicilin esters , anticoagulants,&#xD;
             antineoplastic agents&#xD;
&#xD;
          -  Women who are pregnant or of childbearing&#xD;
&#xD;
          -  Have gastroparesis&#xD;
&#xD;
          -  Current or a history of cancer, with the exception of fully excised skin carcinoma&#xD;
             (Malign Melanoma will be excluded).&#xD;
&#xD;
          -  Have severe concomitant disease (i.e. uncontrolled or insuline dependent diabetes&#xD;
             mellitus, symptomatic bladder stone (patients have asemptomatic, not undergone&#xD;
             colesistit, stone &lt;3cm and polib &lt;1cm can be included), active or unhealed gastric or&#xD;
             duodenum ulcer, Zollinger Ellison syndrome, primary esophageal motility disorder,&#xD;
             pancreatitis, inflammatory bowel disease, chronic hepatic disease, severe lung&#xD;
             disease, uncontrolled kidney failure, cardiac failure, cerebrovascular disease,&#xD;
             epilepsy) which affects the conduct and result of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neutec Ar-Ge San ve Tic A.S</last_name>
    <role>Study Director</role>
    <affiliation>Neutec Ar-Ge Clinical Trial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department Of Gastroenterology, Faculty Of Medicine, Ege University, Izmir, Turkey</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>November 4, 2016</last_update_submitted>
  <last_update_submitted_qc>November 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

